[1] Kakabadze MZ, Paresishvili T, Karalashvili L, et al.Oral microbiota and oral cancer: review[J]. Oncol Rev, 2020, 14(2): 476-482. [2] Chen Y, Shao Z, Jiang E, et al.CCL21/CCR7 interaction promotes EMT and enhances the stemness of OSCC via a JAK2/STAT3 signaling pathway[J]. J Cell Physiol, 2020, 235(9): 5995-6009. [3] 鲁泽, 潘亚萍. 牙龈卟啉单胞菌促进口腔鳞状细胞癌发生机制研究进展[J]. 中国实用口腔科杂志, 2019, 12(10): 617-621. Lu Z, Pan YP.Progress in the study of the mechanism of Porphyromonas gingivalis promoting oral squamous cell carcinoma[J]. Chinese Journal of Practical Stomatology, 2019, 12(10): 617-621. [4] Irfan M, Delgado RZR, Frias-Lopez J.The oral microbiome and cancer[J]. Front Immunol, 2020, 11: 591088. [5] Elmusrati A, Wang J, Wang CY.Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma[J]. Int J Oral Sci, 2021, 13(1): 24-35. [6] 热孜万姑丽·亚森, 买热拍提·买明, 李晨曦, 等. 牙龈卟啉单胞菌促进口腔鳞状细胞癌进展的作用及机制研究进展[J]. 中国口腔颌面外科杂志, 2023, 21(2): 186-190. Reziwanguli YS, Mairepati MM, Li CX, et al.Advances in the role and mechanism of Porphyromonas gingivalis in promoting the progression of oral squamous cell carcinoma[J]. China Journal of Oral and Maxillofacial Surgery, 2023, 21(2): 186-190. [7] Stasikowska-Kanicka O, Wagrowska-Danilewicz M, Danilewicz M.Immunohistochemical analysis of Foxp3+, CD4+, CD8+ cell infiltrates and PD-L1 in oral squamous cell carcinoma[J]. Pathol Oncol Res, 2018, 24(3): 497-505. [8] Wang Z, Wu VH, Allevato MM, et al.Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4[J]. Nat Communicat, 2019, 10(1): 5546. [9] 刘雪, 许立明, 刘朗清, 等. 牙龈卟啉单胞菌上调CCL20的表达对口腔鳞状细胞表型的影响[J]. 新疆医科大学学报, 2024, 47(3): 322-328. Liu X, Xu LM, Liu LQ, et al.Effect of up-regulation of CCL20 expression by Porphyromonas gingivalis on oral squamous cell phenotype[J]. Journal of Xinjiang Medical University, 2024, 47(3): 322-328. [10] Guo ZC, Jing SL, Jumatai S, et al.Porphyromonas gingivalis promotes the progression of oral squamous cell carcinoma by activating the neutrophil chemotaxis in the tumour microenvironment[J]. Cancer Immunol Immunother, 2023, 72(6): 1523-1539. [11] 热孜万姑丽·亚森, 买热拍提·买明, 李晨曦, 等. 牙龈卟啉单胞菌通过CXCL2/CXCR2轴促进口腔鳞癌进展的动物模型研究[J]. 新疆医科大学学报, 2023, 46(5): 575-582. Reziwanguli YS, Mairepati MM, Li CX, et al.Animal model study of Porphyromonas gingivalis promoting oral squamous carcinoma progression through CXCL2/CXCR2 axis[J]. Journal of Xinjiang Medical University, 2023, 46(5): 575-582. [12] Guo ZC, Jumatai S, Jing SL, et al.Bioinformatics and immunohistochemistry analyses of expression levels and clinical significance of CXCL2 and TANs in an oral squamous cell carcinoma tumor microenvironment of Prophyromonas gingivalis infection[J]. Oncol Lett, 2021, 21(3): 189-200. [13] Wang B, Deng J, Donati V, et al.The roles and interactions of Porphyromonas gingivalis and fusobacterium nucleatum in oral and gastrointestinal carcinogenesis: a narrative review[J]. Pathogens, 2024, 13(1): 93. [14] Stasiewicz M, Karpiński TM.The oral microbiota and its role in carcinogenesis[J]. Semin Cancer Biol, 2022, 86(Pt 3): 633-642. [15] Fan R, Zhou Y, Chen X, et al.Porphyromonas gingivalis outer membrane vesicles promote apoptosis via msRNA-regulated DNA methylation in periodontitis[J]. Microbiol Spectr, 2023, 11(1): e0328822. [16] 刘塬, 张凌. 口腔微生物与口腔鳞状细胞癌关系的研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(3): 278-284. Liu Y, Zhang L.Research progress on the relationship between oral microorganisms and oral squamous cell carcinoma[J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(3): 278-284. [17] 庞晓婵, 陈青立, 雒国凤, 等. 牙龈卟啉单胞菌对口腔鳞状细胞癌化疗耐药行为的影响[J]. 口腔医学研究, 2024, 40(5): 413-416. Pang XC, Chen QL, Luo GF, et al.Influence of Porphyromonas gingivalis on chemoresistance behavior of oral squamous cell carcinoma[J]. Oral Medicine Research, 2024, 40(5): 413-416. [18] El-Awady AR, Miles B, Scisci E, et al.Porphyromonas gingivalis evasion of autophagy and intracellular killing by human myeloid dendritic cells involves DC-SIGN-TLR2 crosstalk[J]. PLoS Pathog, 2015, 10(2): e1004647. [19] Fitzsimonds ZR, Rodriguez-Hernandez CJ, Bagaitkar J, et al.From beyond the pale to the pale riders: the emerging association of bacteria with oral cancer[J]. J Dent Res, 2020, 99(6): 604-612. [20] Geng F, Liu J, Guo Y, et al.Persistent exposure to Porphyromonas gingivalis promotes proliferative and invasion capabilities, and tumorigenic properties of human immortalized oral epithelial cells[J]. Front Cell Infect Microbiol, 2017, 7: 57. [21] 黄杰, 葛颂. 牙周主要致病菌与口腔鳞状细胞癌关系的研究进展[J]. 山东医药, 2019, 59(29): 106-109. Huang J, Ge S.Research progress on the relationship between major periodontal pathogenic bacteria and oral squamous cell carcinoma[J]. Shandong Medicine, 2019, 59(29): 106-109. [22] 刘雪. 牙龈卟啉单胞菌通过CCL20-CCR6-treg轴调控口腔鳞状细胞癌恶性表型的研究[D]. 乌鲁木齐: 新疆医科大学, 2024. Liu X.Porphyromonas gingivalis regulates the malignant phenotype of oral squamous cell carcinoma through the CCL20-CCR6-treg axis[D]. Urumqi: Xinjiang Medical University, 2024. [23] Gallimore A, Quezada SA, Roychoudhuri R.Regulatory T cells in cancer: where are we now?[J]. Immunology, 2019, 157(3): 187-189. [24] Nie F, Zhang J, Tian H, et al.The role of CXCL2-mediated crosstalk between tumor cells and macrophages in fusobacterium nucleatum-promoted oral squamous cell carcinoma progression[J]. Cell Death Dis, 2024, 15(4): 277-292. [25] 何俊锋, 白冷媚. 骨关节炎患者血清CCL20和CCR6水平及临床意义[J]. 热带医学杂志, 2023, 23(4): 545-549. He JF, Bai LM.Serum CCL20 and CCR6 levels and clinical significance in patients with osteoarthritis[J]. Journal of Tropical Medicine, 2023, 23(4): 545-549. [26] 董衍垒. CCR6-CCL20趋化因子轴在肝癌过继性免疫细胞治疗中导向作用的研究[D]. 济南: 山东大学, 2023. Huang YL.Study on the guiding role of CCR6-CCL20 chemokine axis in hepatocellular carcinoma transitory immune cell therapy[D]. Jinan: Shandong University, 2023. [27] 王芳元. 肾脏内皮细胞通过CCL5-CCR5和CCL20-CCR6轴募集CD8+ T细胞参与MPO-AAV肾损害[D]. 长沙: 中南大学, 2023. Wang YF.Renal endothelial cells recruit CD8+ T cells via CCL5-CCR5 and CCL20-CCR6 axis involved in MPO-AAV kidney damage[D]. Changsha: Central South University, 2023. [28] Power CA, Church DJ, Meyer A, et al.Cloning and characterization of a specific receptor for the novel CC chemokine MIP-3alpha from lung dendritic cells[J]. J Exp Med, 1997, 186(6): 825-835. [29] Shan F, Somasundaram A, Bruno TC, et al.Therapeutic targeting of regulatory T cells in cancer[J]. Trends Cancer, 2022, 8(11): 944-961. [30] Liu Y, Zheng P.Preserving the CTLA-4 checkpoint for safer and more effective cancer immunotherapy[J]. Trends Pharmacol Sci, 2020, 41(1): 4-12. [31] Harjunpää H, Guillerey C.TIGIT as an emerging immune checkpoint[J]. Clin Exp Immunol, 2020, 200(2): 108-119. [32] 黄秋艺, 徐凌峰, 樊倩妤, 等. 头颈鳞癌免疫治疗超进展的研究现状[J]. 中国肿瘤临床, 2024, 51(21): 1125-1130. Huang QY, Xu LF, Fan Q, et al.Current status of research on hyperprogression of immunotherapy for head and neck squamous carcinoma[J]. China Cancer Clinic, 2024, 51(21): 1125-1130. [33] Cazzato G, Cascardi E, Colagrande A, et al.T cell immunoglobulin and mucin domain 3 (TIM-3) in cutaneous melanoma: a narrative review[J]. Cancers(Basel), 2023, 15(6): 1697. |